Research programme: pancreatic exocrine insufficiency therapy - Novozymes/AbbVie

Drug Profile

Research programme: pancreatic exocrine insufficiency therapy - Novozymes/AbbVie

Alternative Names: SLV 340

Latest Information Update: 01 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novozymes A/S; Solvay
  • Developer AbbVie; Novozymes A/S
  • Class Pancreatic enzymes
  • Mechanism of Action Amylase stimulants; Lipase stimulants; Protease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pancreatic disorders

Most Recent Events

  • 01 Aug 2012 No development reported - Preclinical for Pancreatic disorders in European Union (unspecified route)
  • 31 Mar 2010 Preclinical development is ongoing in European Union
  • 31 Dec 2006 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top